Citi Raises its Price Target on Merck & Co. (MRK) to $125 from $120

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Most Profitable S&P 500 Stocks to Buy Now.

On March 20, 2026, Citi raised the price target on Merck & Co., Inc. (NYSE:MRK) to $125 from $120 and maintained a Neutral rating.

On March 18, 2026, Merck’s Animal Health division announced that the FDA approved an expanded label for Bravecto Quantum in dogs, adding treatment and control for additional tick species for up to 12 months with a single injection. The product, first approved in July 2025, remains available through licensed veterinarians and continues to cover fleas and multiple tick infestations.

Citi Raises its Price Target on Merck & Co. (MRK) to $125 from $120

On March 16, 2026, the company also said new data from its cardio-pulmonary pipeline will be presented at the American College of Cardiology meeting, including results from the Phase 3 CORALreef AddOn trial evaluating enlicitide and the Phase 2 CADENCE trial evaluating Winrevair.

Earlier in March, Wells Fargo raised its price target on Merck & Co., Inc. (NYSE:MRK) to $150 from $135 and maintained an Overweight rating, stating that Sac-TMT could become “best-in-class” and potentially replace chemotherapy across several indications.

Merck & Co., Inc. (NYSE:MRK) develops and markets pharmaceutical and vaccine products across a wide range of therapeutic areas.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.